sur MIRA Pharmaceuticals (NASDAQ:MIRA)
MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Pain Relief Alternative
MIRA Pharmaceuticals has announced that its new oral ketamine analog, Ketamir-2, showed superior pain relief in preclinical studies compared to Gabapentin and Pregabalin. This development highlights Ketamir-2 as a potential alternative for neuropathic pain patients, offering effective relief without the risks associated with opioid use.
The study demonstrated that Ketamir-2 surpassed the effectiveness of Pregabalin by 112% and Gabapentin by 70% at higher doses. Unlike its counterparts, Ketamir-2 presents fewer cognitive side effects and no risk of dependence, making it safer for long-term use.
Given the increasing global concern for neuropathic pain, MIRA aims to submit an Investigational New Drug application by year-end, with Phase 1 clinical trials set for early 2025. The company is also exploring Ketamir-2’s potential for treating PTSD and other neuropsychiatric disorders, seeking government grants to accelerate its development.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MIRA Pharmaceuticals